



Financial Tear Sheet

Corporate Profile

ConforMIS is a medical technology company that uses its proprietary iFit[®] Image-to-Implant[®] technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. ConforMIS offers a broad line of customized knee implants designed to restore the natural shape of a patient's knee. In recent clinical studies, iTotal[®] CR, ConforMIS' cruciate-retaining total knee replacement implant and best-selling product, demonstrated superior clinical outcomes, including better function and greater patient satisfaction compared to traditional, off-the-shelf implants. ConforMIS owns or exclusively in-licenses approximately 500 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints and other elements of the iFit[®] Image-to-Implant[®] technology platform. ConforMIS believes its iFit[®] Image-to-Implant[®] technology platform has application to other major joints in the worldwide market for joint replacement products. For more information visit www.conformis.com.

Primary IR Contact

Investor Relations

Oksana Bradley

Phone: (781) 374-5598

E-mail: ir@conformis.com

Stock Performance

CFMS (Common Stock)

Exchange NASDAQ GS (US Dollar)

Financial Status Indicator C

Price \$2.40

Change (%) ▲ 0.07 (3.00%)

Volume 56,793

52 Week High \$8.61

52 Week Low \$2.21

Market Cap \$108,702,175

Rolling EPS -1.34

PE Ratio 0

Shares Outstanding 45,292,573

Data as of 01/19/18 4:00 p.m. ET



Recent Headlines

01/08/18

[ConforMIS Reports Preliminary Fourth Quarter and Year-End 2017 Revenue Results; Provides 2018 Financial Guidance](#)

01/04/18

[ConforMIS Announces Publication of Results published in the peer-reviewed Journal of Knee Surgery showing 100% of patients treated with iTotal CR achieve mechanical alignment in target range of +/- 3%](#)

11/01/17

[ConforMIS Reports Third Quarter 2017 Financial Results](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

| Filing Date | Form |
|-------------|----------|
| 01/10/18 | SC 13G/A |
| 01/08/18 | 8-K |
| 12/22/17 | 8-K |
| 12/20/17 | 4 |

Corporate Governance

| | |
|--|---|
| Mark Augusti, MBA | Chief Executive Officer and President |
| Paul Weiner, CPA | Chief Financial Officer |
| Daniel Steines, MD, MS | Chief Technology Officer |
| David Cervený, JD | Chief Legal Officer and General Counsel |
| Emmanuel Nyakako | Senior Vice President, Quality and Regulatory Affairs |
| Marc Quartulli | Vice President, Clinical Affairs |
| John Slamin | Senior Vice President, Knee Implant Engineering |
| Dan Krupp | Senior Vice President, US Sales |
| Lisa Donnelly | SVP, Global Marketing |

Data provided by Nasdaq. Minimum 15 minutes delayed.